Clinical trialsCompany release

ADC Therapeutics to present ZYNLONTA lymphoma data in five oral talks at ASH 2026

🇺🇸 ADC Therapeutics SA (ADCT) · Wed 04 Nov 2026

The company has released abstracts covering LOTIS-7, a marginal zone lymphoma trial and full Phase 3 LOTIS-5 results, including a progression-free survival gain and higher Grade 5 event rates.

ADC Therapeutics SA said on 4 November 2026 that it has released abstracts for the American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans from 12 to 15 December. The abstracts cover ZYNLONTA (loncastuximab tesirine) in B-cell lymphomas and will be presented in five oral talks.

In LOTIS-7, ZYNLONTA was combined with glofitamab in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The abstract reports an overall response rate (ORR) of 88.7%. A separate investigator-led trial in marginal zone lymphoma reports an ORR of 93%.

The meeting will also include full results from the Phase 3 LOTIS-5 trial. These show a progression-free survival (PFS) advantage over R-GemOx, with a hazard ratio of 0.73.

On safety, the LOTIS-5 data show Grade 5 events (events with a fatal outcome) in 13.2% of patients, compared with 4.6% in the comparator arm, within the 105-day reporting window. The summary available does not give further detail on the causes of these events or on other safety findings.

What it means for your team

  • Regulatory teams should review the full LOTIS-5 abstract and presentation, as the PFS benefit (HR 0.73) will be weighed against the higher Grade 5 event rate (13.2% vs 4.6%).
  • Pharmacovigilance teams may want to examine how the 105-day reporting window shapes the fatal-event comparison and what causes drove the imbalance.
  • Market-access teams should note that the LOTIS-7 and marginal zone lymphoma figures come from single-arm or investigator-led settings, so cross-trial comparisons need caution.

Company's press release (SEC filing): ADC Therapeutics SA ↗

Article written by VigiEye from the official source (ADC Therapeutics SA). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →